MedPath

A prospective, randomized, open-label parallel-group clinical study to investigate effects and maneuverability of device of fluticasone/formoterol pMDI (Flutiform) vs. fluticasone/salmeterol DPI (Adoair Diskus) in patients who have poorly controlled asthma

Not Applicable
Conditions
Bronchial asthma
Registration Number
JPRN-UMIN000012330
Lead Sponsor
KYORIN Pharmaceutical Co., Ltd.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
24
Inclusion Criteria

Not provided

Exclusion Criteria

(1) Patients who have experienced adverse drug reactions caused by treatment with an ICS, LABA, or concomitant use or a combination of ICS and LABA (2) Patients with severe cardiac, hepatic, renal, pulmonary, or hematologic disease (3) Patients with complications of apparent chronic obstructive pulmonary disease (COPD) (4) Patients with complications of malignant tumors (5) Patients with a history of smoking within the past 1 year (6) Patients who are pregnant, lactating, or desire to conceive during the study period (7) Patients who were judged unsuitable for enrollment in the study by the investigator or the sub-investigator

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Comparison of FEV1 at week 2
Secondary Outcome Measures
NameTimeMethod
- ACQ - %FEV1, FEV1%, FEV1 - PEF - FeNO - Scores for Leicester Cough Questionnaire - Number of days when therapeutic drugs for asthma attacks are used, number of days when asthma symptoms are present, and asthma symptom score - Symptom score for cough - Questionnaire scores on inhaler (device maneuverability)
© Copyright 2025. All Rights Reserved by MedPath